GlassScriptPhysician profile
Thomas F Cozzi
NPI 1013924489
$3,227.44
in general payments reported to CMS, 2019-2025
19 companies · $859 in 2025
The $859 reported for 2025 was more than what 87% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $239 · 2021: $19.47 · 2022: $197 · 2023: $408 · 2024: $1,222 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,489.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $582.78 | 2020-2025 | Jardiance |
| Novo Nordisk INC | $462.43 | 2019-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $373.71 | 2024-2025 | Rexulti |
| Abbott Laboratories | $329.16 | 2023-2024 | Proclaim, Freestyle Libre 3, Eterna |
| Astrazeneca Pharmaceuticals LP | $244.19 | 2024 | Farxiga |
| Glaxosmithkline, LLC. | $238.77 | 2020-2024 | Shingrix |
| Lilly USA, LLC | $213.69 | 2019-2025 | |
| Corcept Therapeutics | $212.85 | 2024 | Korlym |
| Amarin Pharma, INC. | $110.17 | 2019 | |
| Alexion Pharmaceuticals, INC. | $86.61 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.25 | 2025 | |
| Horizon Therapeutics Plc | $84.00 | 2022 | |
| Neurocrine Biosciences, INC. | $78.58 | 2023 | Ongentys |
| Abbvie INC. | $33.33 | 2024 | |
| Edwards Lifesciences Corporation | $28.93 | 2025 | Sapien 3 Ultra Resilia |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $19.47 | 2021 | |
| Cipher Pharmaceuticals US LLC | $16.54 | 2025 | Spinosad, Natroba |
| Sumitomo Pharma America, INC. | $13.61 | 2023 | Gemtesa |
| Smith+Nephew, INC. | $12.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cozzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.